Significant Price Target Increase for Aquestive Therapeutics
Lake Street Raises Price Target for Aquestive Therapeutics
Lake Street Capital Markets recently revised its outlook on Aquestive Therapeutics, a pharmaceutical company, by increasing its price target on the stock. The new target is now set at $8.00, a substantial increase from the previous $3.00 target, while maintaining a Buy rating on the shares.
Anticipation for FDA Decision on Aquestive Therapeutics
2024 is shaping up to be an eventful year for Aquestive Therapeutics as they await an FDA decision on their drug, Libervant, a treatment for epilepsy. Approval may come as early as April, with the company also gearing up for the submission of a New Drug Application (NDA) for Anaphylm, a severe allergic reaction treatment.
Positive Revenue Reports and Future Milestones
With fourth-quarter revenues exceeding expectations at $13.2 million, Aquestive Therapeutics is on a positive trajectory. This, coupled with upcoming milestones, such as the potential approval of Libervant and the NDA submission for Anaphylm, has led Lake Street Capital Markets to revise their price target upwards.
Analyst Confidence and Growth Potential
Lake Street Capital Markets’ analyst expressed confidence in Aquestive Therapeutics’ future, highlighting the value-generating prospects tied to upcoming milestones. The firm sees significant value in the company’s near-term opportunities, especially with the anticipated FDA approval and NDA submission.
Market Watch and Investor Interest
Aquestive Therapeutics’ journey through these regulatory milestones will be closely monitored by investors and market observers due to the potential impact on the company’s valuation and market performance. The market awaits these developments eagerly to gauge the company’s growth prospects.
